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Tobacco use has been associated with poorer outcomes after liver transplantation (LT). Our study examined the effect on LT 
listing outcomes of a newly implemented policy prohibiting the use of all tobacco products compared with a prior restrictive 
policy. Medical records of consecutive adult patients evaluated for LT from January 2010 to July 2013 (era 1, n = 1344) and 
August 2013 to March 2017 (era 2, n = 1350) were reviewed. The proportion of LT candidates listed was the primary outcome. 
The mean age of the 2694 LT candidates was 54 ± 11 years, 60% were male, and the mean Model for End-Stage Liver Disease 
(MELD) score was 15 ± 7. Although the proportion of LT candidates who were smokers was significantly higher in era 2 (33% 
versus 23%; P < 0.005), the proportion of smokers listed for LT remained stable (13% versus 17%; P = 0.25). However, there 
were more smokers excluded for ongoing tobacco use in era 2 compared with era 1 (9.6% versus 4.4%; P = 0.001). Factors 
independently associated with LT listing included a diagnosis of hepatocellular carcinoma, being married, private insurance, 
absence of psychiatry comorbidity, and absence of tobacco, marijuana, or opiate use but evaluation during era 2 was not associ-
ated with LT listing. However, the median time to listing significantly increased over time, especially in smokers (from 65 to 
122 days; P = 0.001), and this trend was independently associated with evaluation during era 2, a lower MELD score, not hav-
ing children, and a lower level of education (P < 0.05). In conclusion, despite an increasing incidence of active smokers being 
referred for LT evaluation, the proportion of smoker candidates listed for LT was unchanged after instituting our prohibitive 
tobacco use policy. However, the time to get on the waiting list for smokers who were eventually listed was significantly longer 
due to the need to achieve complete tobacco cessation.
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Liver transplantation (LT) is a lifesaving interven-
tion for patients with decompensated cirrhosis and 
other forms of liver failure. However, because of the 
ongoing shortage of donor organs, candidate selection 
presents unique ethical issues. The principles of organ 
allocation are utility (maximize benefit), justice (fair 
distribution of access to transplantation), and respect 
of individual autonomy. Active abuse of alcohol, illicit 
substances, and certain psychosocial behaviors, such 
as poor compliance, inadequate social support, and 
uncontrolled psychiatric disorders, are generally con-
sidered relative to absolute contraindications to LT.(1)
Tobacco use is a well-recognized risk factor for heart 
and lung disease, stroke, peripheral vascular disease, 
cancer, and other causes of death in the general popu-
lation.(2) Active smokers also have an increased risk of 
infections as well as biliary and vascular complications 
after LT.(3-5) Although the American Association for 
the Study of Liver Diseases (AASLD) practice guide-
line recommends that tobacco consumption should be 
prohibited in all LT candidates, a recent study showed 
substantial variation in tobacco use policies among LT 
centers.(6,7)
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Our program implemented a prohibitive tobacco use 
policy on August 1, 2013, wherein all LT candidates 
were required to abstain completely from tobacco as 
well as alcohol, marijuana, and other illicit substances. 
Prior to the implementation of this prohibitive tobacco 
use policy, only LT candidates with coronary artery 
disease and lung disease were required to stop using 
tobacco products (restrictive policy). The aim of this 
study was to examine the impact of this policy change 
on LT listing outcomes with the hypothesis that the 
prohibitive policy would be associated with a lower 
overall rate of LT listing among smokers being eval-
uated for LT and a longer time to listing among the 
smokers who are eventually listed.
Patients and Methods
patient cOhOrt
The University of Michigan institutional review board 
priorly approved this retrospective chart-review study. 
All adult LT candidates over 18 years of age evaluated 
at the University of Michigan from January 1, 2010, to 
March 1, 2017, were included. Pediatric, living donor, re-
peat evaluations, and patients with missing data were ex-
cluded. All patients were evaluated by a multidisciplinary 
team of hepatologists, surgeons, and social workers. Data 
were abstracted from electronic medical records.
Data cOllectiOn
Abstracted demographic features included patient age, 
sex, race, etiology of liver disease, Model for End-Stage 
Liver Disease (MELD) score (at evaluation, listing, 
and transplant), and insurance, employment, and mar-
ital status. Tobacco, alcohol, and illicit substance use 
history were coded as never used, remote use (more 
than 12 months ago), and current user or any use within 
the past 12 months before evaluation. History of prior 
substance use–related health or legal consequences, 
psychiatric comorbidities, and prior substance use– 
related treatments were collected. Toxicology screen-
ing at the initial LT evaluation and other prelisting 
test results were collected and analyzed.
DeFinitiOns
The period from January 1, 2010, to July 31, 2013, 
when only patients with coronary artery disease and 
lung disease were required to stop smoking, was de-
fined as era 1 (restrictive tobacco). In contrast, the 
period from August 1, 2013, to March 1, 2017, when 
all LT candidates were required to abstain completely 
from tobacco products, was defined as era 2 (prohib-
ited tobacco). During both eras, patients were encour-
aged to stop using tobacco products and asked to sign 
a substance use contract that prohibited them from 
drinking alcohol, using marijuana, or taking other 
illicit substances. There was no minimum duration of 
tobacco abstinence required, but a negative urine to-
bacco metabolite test was required prior to listing. In 
addition, other aspects of the substance use contract 
and policy in our center were not changed with im-
plementation of the prohibitive policy. Patients who 
violated the substance use policy were either removed 
from the waiting list or required to complete substance 
use rehabilitation and reactivated for LT only after 
having negative toxicology screens.
Patients with a history of tobacco use within the 
past 12  months were categorized as smokers. An 
active smoker was determined by disclosure to staff 
from self or family member or by detectable serum 
or urine metabolites. Urine cotinine was used to 
screen for active nicotine use, whereas urinary anab-
asine was used to confirm active cigarette use in 
patients receiving nicotine replacement therapy.(8) 
Serum ethanol, phosphatidylethanol, and urine ethyl 
glucuronide were used to screen for alcohol use in 
patients with alcoholic liver disease (ALD).(9) Active 
marijuana use was confirmed by a positive urine can-
nabinoid screen. Other toxicology screens included 
urine amphetamine, cocaine, opiate, oxycodone, 
benzodiazepines, and barbiturates to screen for illicit 
substance use. The frequency of substance use inter-
ventions, including referral to tobacco consultation 
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service, psychology or psychiatry, and substance use 
pharmacotherapy, were collected.
OutcOMe Measures
The LT selection outcome included being listed for 
LT, time from initial LT evaluation to listing (time 
to listing), and the reasons for patients being excluded 
from LT listing. Graft and patient survival data were 
collected at 1  year and last available follow-up until 
June 30, 2018.
statistical analYsis
Continuous variables were expressed as mean ± stan-
dard deviation, and categorical variables were expressed 
as percentages. The baseline characteristics at the time 
of LT evaluation were compared using an independent 
sample t test for continuous variables and chi-square 
tests for categorical data. The primary outcomes were 
either being listed or not listed and the time from 
evaluation to listing (time to listing). A simple linear 
regression analysis was used to predict the proportion 
of liver disease diagnosis and the time to listing based 
on the year of evaluation. We used multivariate logis-
tic regression analysis to assess the candidate factors 
associated with listing status and the time-to-listing 
period (≥90  days). These models were adjusted for 
age, policy, MELD score, presence of hepatocellular 
carcinoma (HCC), insurance status, marital status, 
substance use history, prior substance-use disorder 
(SUD) consequences, and psychiatric comorbidities. 
We performed subgroup analysis in era 1 comparing 
the patient and graft survival using the Kaplan-Meier 
method stratified by smoking status and log-rank 
analysis. SPSS, version 25.0 (IBM Corp., Armonk, 
NY) was used for all analyses.
Results
patient characteristics
From January 1, 2010, to March 1, 2017, 3045 adults 
underwent LT evaluation. In total, 351 patients were 
excluded from the analysis, including 24 living donor 
evaluations, 6 patients with incomplete data, and 321 
duplicate evaluations. Among the remaining 2694 
patients, 1344 underwent LT evaluation in era 1 and 
1350 underwent LT evaluation in era 2 (Fig. 1).
The clinical characteristics of the patients are 
shown in Table 1. The mean age of the 2694 patients 
was 54  ±  11  years, 60% were male, and 84% were 
Caucasian. Interestingly, the number of smokers was 
significantly higher in era 2 compared with era 1 (33% 
versus 23%; P  <  0.005). Overall, smokers were sig-
nificantly younger compared with nonsmokers in both 
eras (P < 0.005). The mean MELD score of the entire 
cohort was 15 ± 7. The mean MELD score of smok-
ers was lower than the nonsmokers in era 2 (14 ±  7 
versus 15 ± 7; P = 0.008), and it was also lower than 
the MELD scores of the era 1 smokers (14 ± 7 versus 
15 ± 8; P = 0.03). In both eras, smokers were more 
likely to have ALD, HCC, and viral hepatitis as the 
causes of their liver disease. The underlying causes of 
Fig. 1. LT candidates included in this study. Among the 1344 
LT candidates in era 1, 337 were listed for LT. Among the 1350 
LT candidates in era 2, 331 were listed for LT. As of June 1, 2017, 
a total of 212 and 177 candidates underwent transplantation 
during era 1 and era 2, respectively.
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taBle 1. clinical characteristics of 2694 patients evaluated for lt stratified by smoking status and era
Variables








(n = 898) P Value Smokers Nonsmokers
Age at evaluation, years 51 ± 10 54 ± 11 <0.005† 52 ± 10 56 ± 12 <0.005† 0.12 0.001†
Sex, male 62 56 0.06 60 60 0.98 0.56 0.08
Race, white 83 82 0.51 84 86 0.05 0.42 0.12
MELD score at evaluation‡ 15 ± 8 15 ± 8 0.53 14 ± 7 15 ± 7 0.008† 0.03† 0.64†
Diagnosis
Viral hepatitis 45 29 <0.05† 37 21 <0.05† <0.05† <0.05†
ALD 31 24 <0.05† 40 27 <0.05† <0.05† <0.05†
NASH 3 10 <0.05† 5 18 <0.05† <0.05† <0.05†
Others 21 37 <0.05† 18 34 <0.05† NS NS
Presence of HCC 15 11 0.08 13 10 0.05 0.39 0.20
Insurance status, Medicaid 27 12 <0.005† 39 18 <0.005† 0.001† <0.005†
Education level, college or higher 52 57 0.14 58 64 0.04† 0.11 0.002†
Employment status, unemployed 60 52 0.02† 68 53 <0.005† 0.02† 0.69
Marital status, married 53 68 <0.005† 48 63 <0.005† 0.15 0.02†
Parental status, has children 74 80 0.02† 81 82 0.5 0.03† 0.24
Reported substance use history
Lifetime tobacco use 100 23 <0.005† 100 42 <0.005† NS <0.005†
Lifetime alcohol use 84 63 <0.005† 86 64 <0.005† 0.34 0.65
Lifetime marijuana use 35 17 <0.005† 42 18 <0.005† 0.04† 0.48
Lifetime opiate use 25 9 <0.005† 26 13 <0.005† 0.82 0.02†
Lifetime other illicit substance use 18 8 <0.005† 25 8 <0.005† 0.02† 0.59
Tobacco use within 12 months 100 — <0.005† 100 — <0.005† NS NS
Alcohol use within 12 months 37 20 <0.005† 49 27 <0.005† 0.001† 0.001†
Marijuana use within 12 months 16 5 <0.005† 26 8 <0.005† 0.001† 0.009†
Opiate use within 12 months 23 7 <0.005† 23 12 <0.005† 0.97 0.003†
Illicit substance use within 
12 months
1.9 0.3 <0.005† 2.7 0.3 <0.005† 0.5 0.87
Presence of psychiatry comorbidity 32 18 <0.005† 48 29 <0.005† <0.005† <0.005†
On psychiatric medications 21 11 <0.005† 31 23 0.002† <0.005† <0.005†
Prior SUD health/legal 
consequences
11 5 <0.005† 27 10 <0.005† <0.005† <0.005†
Prior SUD treatment 17 7 <0.005† 30 12 <0.005† <0.005† <0.005†
Toxicology screen
Toxicology screening, test 
completed
79 70 0.007† 80 72 0.001† 0.97 0.58
Alcohol metabolites, positive 5 1.9 0.02† 8 3.4 0.002† 0.14 0.08
Tobacco metabolites, positive 61 6 <0.005† 55 7 <0.005† 0.14 0.36
Marijuana metabolites, positive 15 7 <0.005† 17 8 <0.005† 0.40 0.18
Opiate metabolites, positive 31 18 <0.005† 22 17 0.05 0.01† 0.78
Other illicit substances metabo-
lites, positive
2.8 1.4 0.14 3.1 2.2 0.4 0.84 0.26
Counseling/referral 31 11 <0.005† 46 21 <0.005† <0.005† <0.005†
SUD pharmacotherapy 1.5 0 0.004† 2.2 2 <0.005† 0.53 0.26
NOTE: Data are given as mean ± standard deviation or as percentages.
*P value for era 1 versus era 2.
†Univariate analysis P < 0.05.
‡Calculated MELD score, not MELD-sodium.
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liver disease significantly changed with the propor-
tion of patients with ALD significantly increasing in 
era 2 (27% to 34%; P < 0.05), whereas viral hepatitis 
decreased (37% to 29%; P < 0.05) (Fig. 2). A simple 
linear regression analysis was used to predict propor-
tion of liver disease diagnosis based on the year of eval-
uation. Each year an increase in referral for evaluation 
was associated with a 2.8% decrease in the propor-
tion of LT candidates with viral hepatitis (β = –0.028 
[95% confidence interval [CI], –0.037 to –0.018]; 
P < 0.001), 2% increase in ALD (β = 0.02 [95% CI, 
0.007-0.03]; P  =  0.007), and 1.0% increase in non-
alcoholic steatohepatitis (NASH; β = 0.01 [95% CI, 
0.002-0.019]; P = 0.03). Furthermore, smokers in both 
eras were significantly more likely to have Medicaid 
insurance, be unemployed, and less likely to be married 
(P < 0.005).
suBstance use anD 
psYchiatric histOrY
In both eras, smokers reported more lifetime history of 
alcohol (84% versus 63% and 86% versus 64%), mar-
ijuana (35% versus 17% and 42% versus 18%), opiate 
(25% versus 9% and 26% versus 13%), and other il-
licit substance use (18% versus 8% and 25% versus 8%) 
compared with nonsmokers (P < 0.005). In addition, 
the rates of lifetime marijuana (42% versus 35%) and 
illicit substance use (25% versus 18%) was higher in 
smokers in era 2 compared with era 1, although life-
time opiate use increased in nonsmokers in era 2 (13% 
versus 9%; P < 0.05; Table 1).
As expected, smokers reported more frequent history 
of alcohol (37% versus 20% and 49% versus 27%), mar-
ijuana (16% versus 5% and 26% versus 8%), opiate (23% 
versus 7% and 23% versus 12%), and illicit substance 
use (1.9% versus 0.3% and 2.7% versus 0.3%) within the 
12  months before LT evaluation compared with non-
smokers (P <  0.005). In era 2, the reported history of 
alcohol and marijuana use within 12 months increased in 
both smokers (era 1 to era 2, 37% to 49% and 16% to 26%, 
respectively) and nonsmokers (era 1 to era 2, 20% to 27% 
and 5% to 8%, respectively), whereas reported history of 
opiate use within 12  months increased in nonsmokers 
only (era 1 to era 2, 7% to 12%; P = 0.003; Table 1).
Smokers also reported more health or legal con-
sequences related to substance use, SUD treatment 
experience, underlying psychiatric comorbidities, and 
psychiatric medication use compared with nonsmokers 
(P < 0.005). In addition, all of these rates significantly 
increased in era 2 compared with era 1 in both smokers 
and nonsmokers (P < 0.005; Table 1).
tOXicOlOgY results anD 
interventiOns
Smokers in both eras were significantly more likely to 
have toxicology testing completed as part of their LT 
evaluation compared with nonsmokers, but the rates 
were high in all groups (Table 1). Although alcohol, 
tobacco, and marijuana metabolites were more fre-
quently detected in smokers in both eras (P < 0.05), 
there was no difference seen between the 2 eras. Both 
smokers and nonsmokers received more interventions 
for various SUDs in era 2 versus era 1, including sub-
stance-use counseling, psychology or psychiatry refer-
ral (46% versus 31% in smokers and 21% versus 11% 
in nonsmokers; P < 0.005). In addition, smokers re-
ceived more SUD pharmacotherapy compared with 
nonsmokers, but there was no significant difference 
between the 2 eras (Table 1).
lt evaluatiOn OutcOMes
Although the proportion of candidates listed for LT 
were similar in both eras (25% versus 24%; P = 0.14), a 
significantly lower proportion of smokers versus non-
smokers were listed in both eras (13% versus 28% in 
era 1 and 17% versus 30% in era 2; P < 0.005; Table 2). 
The proportion of patients not listed for being clini-
cally too well, medical issues, and other reasons were 
similar in both eras. However, the proportion of smok-
ers excluded for ongoing tobacco use was significantly 
higher in era 2 compared with era 1 (4.4% versus 9.6%; 
P = 0.001; Table 2). Interestingly, the median time to 
listing was similar in the smokers and nonsmokers in 
era 1 (65 versus 81 days; P = 0.59). However, the me-
dian time to listing significantly increased in the era 2 
smokers compared with the nonsmokers (122 versus 
105 days; P = 0.01; Table 2). In reviewing these data 
more carefully, the temporal trend of time to listing 
was increasing in both smokers and nonsmoker pa-
tients over the entire time of this study (Fig. 3). In an 
unadjusted linear regression analysis, every year in-
crease in referral for evaluation was associated with a 
6.1-day increase in time to listing on average (β = 0.51 
[95% CI, 0.178-0.842], P  =  0.003 for all LT candi-
dates; β  =  1.176 [95% CI, 0.399-1.954], P  =  0.004 
for smokers; and β  =  0.453 [95% CI, 0.095-0.811], 
P  =  0.01 for nonsmokers). On multivariate analysis, 
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a diagnosis of HCC, being married, male sex, higher 
MELD score, absence of prior SUD-related health 
or legal consequences, absence of psychiatric comor-
bidities, and absence of tobacco, marijuana, or opiate 
use within 12  months were predictive factors for an 
LT candidate being listed (Table 3). Predictive fac-
tors associated with a time to listing exceeding 90 days 
include presence of prior SUD-related health or legal 
consequences, presence of any substance use within 
12  months, and screening positive for tobacco or 
Fig. 2. Liver disease diagnoses among LT candidates seen from 2010 to 2017. Over time, the proportion of LT candidates with ALD 
and NASH significantly increased while the proportion with viral hepatitis decreased (P < 0.001). *P < 0.05.
taBle 2. selection Outcomes stratified by eras and smoking status








(n = 898) P Value Smokers Nonsmokers
Selection results, listed 52 (17) 285 (28) <0.005† 61 (13) 270 (30) <0.005† 0.25 0.25
Time to listing, days 65 (0-342) 81 (0-519) 0.59 122 (0-481) 105 (0-546) 0.014† 0.001† <0.005†
Reason not listed
Clinically too well 89 (28) 252 (24) 0.18 106 (23) 202 (22) 0.69 0.13 0.30
Deceased 10 (3) 43 (4) 0.42 27 (6) 68 (8) 0.28 0.75 0.001†
Medical issue 58 (18) 217 (21) 0.3 54 (12) 186 (21) <0.005† 0.01† 0.84
Alcohol use 45 (14) 104 (10) <0.04† 62 (14) 88 (10) <0.03† 0.82 0.82
Tobacco use 14 (4.4) 6 (0.6) <0.005† 50 (9.6) 2 (2.2) <0.005† 0.001 0.22
Other substance use 8 (3) 18 (2) 0.37 10 (2.2) 23 (2.6) 0.69 0.76 0.21
Others 39 (12) 104 (10) 0.46 82 (18) 59 (6) 0.51 0.93 0.08
Transplanted (% of listed) 34 (65%) 178 (62%) 0.69 25 (41%) 152 (56%) 0.03† 0.01† 0.14
Mean MELD# score at LT‡ 24 ± 6 23 ± 6 0.17 25 ± 6 25 ± 6 0.43 0.51 0.008
NOTE: Data are given as median (range), mean ± standard deviation, or n (%).
*P value for era 1 versus era 2.
†Univariate analysis P < 0.05.
‡Calculated or exceptional MELD score, not MELD-sodium.
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marijuana metabolites. In contrast, being evaluated 
in era 1, higher MELD score, having children, and a 
higher education level were all significantly associated 
with a shorter evaluation time (Supporting Table 1).
transplant OutcOMes
In era 1, 8 (2.4%) of the 337 listed patients were re-
moved from the waiting list due to alcohol (n  =  4), 
tobacco (n = 3), or marijuana (n = 1) use. In era 2, 13 
(3.9%) of the 331 listed patients were removed from 
the waiting list due to either alcohol (n = 6), tobacco 
(n = 6), or marijuana (n = 1) use. There was no differ-
ence in the rate of wait-list removal due to substance 
use between the 2 eras (P = 0.58).
The proportion of smokers undergoing LT during 
follow-up decreased in era 2 compared with era 1 (41% 
versus 65%; P  =  0.01), presumably due to lead-time 
bias. The median (range) time of follow-up after list-
ing was 2191 (3-3025) days in era 1 smokers, 1873 
(0-3038) days in era 1 nonsmokers, 882 (154-1638) 
days in era 2 smokers, and 772 (4-1696) days in era 
2 nonsmokers (Table 4). The mean MELD score at 
transplantation in nonsmokers increased in era 2 (25 
versus 23; P = 0.008), whereas there was no difference 
between smokers (Table 2).
graFt anD patient survival
From era 1, 212 listed patients had undergone LT, 
whereas 177 of the era 2 patients had undergone LT. 
In era 2, 20 patients were excluded from the graft and 
Fig. 3. Days from evaluation to listing among LT candidates seen from 2010 to 2017. Using a linear regression analysis, the median 
time to listing significantly increased for the overall cohort (P = 0.003), smokers (P = 0.004), and nonsmokers (P = 0.01).
taBle 3. Factors associated With Being listed for lt 
among 2694 lt candidates
Variable OR* 95% CI P Value
Sex, male 1.24 1.02-1.53 0.04
Higher MELD score at evaluation 1.03 1.02-1.04 <0.005
Married 1.59 1.27-1.99 <0.005
Medicaid insured 0.48 0.36-0.65 <0.005
Presence of HCC 2.48 1.85-3.33 <0.005
Absence of prior SUD health/legal 
consequences
1.48 1.00-2.16 0.04
Absence of psychiatric comorbidity 1.43 1.12-1.82 0.004
Absence of tobacco use within 
12 months
1.43 1.02-2.02 0.04
Absence of marijuana use within 
12 months
1.53 1.01-2.33 0.04
Absence of opioid use within 
12 months
3.72 2.3-6.02 <0.005
*Adjusted for age, policy, MELD score, presence of HCC, in-
surance status, marital status, substance use history, prior conse-
quences, and psychiatry comorbidity.
likhitsup et al. liver transplantatiOn,  august 2019
1172 | Original article
patient survival outcome analysis due to survival data 
was not available at the time of this analysis. The me-
dian follow-up time after LT was 1923 (0-3038) days 
in era 1 and 796 (4-1696) days in era 2 (P < 0.05). The 
1-year graft and patient survival rates were 88% and 
87%, respectively, in era 1 and 96% and 96%, respec-
tively, in era 2. The 1-year patient and graft survival 
rates were similar among smokers and nonsmokers in 
both eras (Table 4).
A subgroup analysis for LT outcome in era 1 patients 
was performed to evaluate associations between smok-
ing status and graft or patient survival. The 1-year 
graft and patient survival rates in smokers were simi-
lar to nonsmokers (88% versus 88% graft survival and 
88% versus 87% patient survival; P > 0.05). However, 
during a median follow-up time of 2191 (3-3025) days 
in smokers and 1873 (0-3038) days in nonsmokers, the 
graft survival was significantly lower in smokers com-
pared with nonsmokers (73.5% versus 89.7%; P = 0.01). 
In contrast, overall patient survival was slightly lower 
in the smokers but not significantly different than the 
nonsmokers (70.6% versus 78.7%; P = 0.30; Table 4). 
Using a Kaplan-Meier analysis, the unadjusted graft 
survival rate was significantly lower in smokers com-
pared with nonsmokers (P = 0.04), but no significant 
difference in patient survival was noted (P = 0.40; Fig. 
4). Although the cumulative incidence of graft loss 
was significantly higher in era 1 smokers compared 
with nonsmokers, the causes of graft loss were similar 
(Supporting Table 2).
Discussion
Cigarette smoking is a well-recognized cause or co-
factor for a variety of diseases, including heart disease, 
stroke, peripheral vascular disease, lung disease, and 
many types of cancer.(2) Tobacco use is responsible for 
over 6 million annual deaths worldwide with many 
of these deaths occurring in younger adults.(10) In the 
United States, an estimated 480,000 annual deaths are 
attributed to cigarette smoking and secondhand expo-
sure.(11) In 2016, 37.8 million or 15.5% of US adults were 
current cigarette smokers. The highest prevalence of to-
bacco use is among men and those aged 25-64 years.
In patients with cirrhosis, tobacco consumption is a 
major risk factor for both bone and kidney disease.(12) 
Smokers with cirrhosis are also more likely to have asci-
tes and encephalopathy at LT referral compared with 
nonsmokers.(13) Mangus et al. reported that current 
and previous smokers were more likely to have HCC 
in their explant compared with lifetime nonsmokers 
(25% and 29% versus 18%; P <  0.001).(14) Our data 
also demonstrated a trend toward more frequent HCC 
among smokers compared with nonsmokers in both 
eras 1 and 2 (P ≥ 0.05).
The rate of biliary complications after LT was 92% 
higher in active smokers compared with lifetime non-
smokers (hazard ratio, 1.92; 95% CI, 1.07-3.43).(4) The 
incidence of post-LT hepatic arterial thrombosis or ste-
nosis is increased in patients with a history of cigarette 
smoking compared with those without a smoking his-
tory (17.8% versus 8%). Smoking cessation for 2 years or 
more before LT significantly reduced the risk of vascular 
complications after LT (13.5% versus 4.8%).(3) Although 
taBle 4. posttransplant Outcomes stratified by era and smoking status
Outcomes







(n = 134) P Value Smokers Nonsmokers
Post-LT follow-up, days 2191 (3-3025) 1873 (0-3038) 0.14 882 (154-1638) 772 (4-1696) 0.78 0.005‡ <0.005‡
1-year graft survival 88.2 88.2 0.99 100.0 94.8 0.26 0.08 0.04‡
1-year patient survival 88.2 87.1 0.85 95.7 95.5 0.98 0.33 0.01‡
Overall graft survival 73.5 89.7 0.01‡ 100.0 96 0.32 0.006‡ 0.03‡
Overall patient survival 70.6 78.7 0.30 92 95.4 0.47 0.04‡ <0.005
NOTE: Data are given as median (range) or percentage.
*20 patients were excluded due to incomplete survival data.
†P value for era 1 versus era 2.
‡Univariate analysis P < 0.05.
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Fig. 4. Kaplan-Meier curve of patient and graft survival. Among the 212 LT recipients from era 1, smokers had a significantly lower 
rate of (A) graft survival (P = 0.04), although (B) overall survival was not different (P = 0.40).
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there are insufficient data to support how long LT candi-
dates should be abstinent from tobacco before LT listing, 
we require that all smokers have repeatedly negative urine 
metabolite screens on 2 consecutive occasions before plac-
ing them on the waiting list. In addition, all smokers in 
our program are referred to formal tobacco cessation pro-
grams, many of which use adjuvant bupropion or vareni-
cline treatment to help achieve tobacco abstinence. In 
addition, smokers with active anxiety or depressive symp-
toms are frequently referred to psychiatry to help them 
achieve sustained abstinence from tobacco before LT, 
but further studies are needed on the optimal approach. 
Many published studies have also shown that smoking is 
associated with a higher risk of malignancy after LT.(14-18) 
Smoking has also been associated with increased overall 
cardiovascular- and sepsis-related mortality in LT recip-
ients.(19) McConathy et al. also reported that smokers 
had a longer mean length of stay and higher hospital 
costs compared with nonsmokers, although 1-year sur-
vival was the same.(13) Similar to these studies, our data 
showed that 1-year graft and patient survival were com-
parable between smokers and nonsmokers in era 1, but 
with more prolonged follow-up, both patient and graft 
survival were significantly lower for the smokers (Table 4; 
Fig. 4). However, the causes of death appear to be quali-
tatively similar in the 2 groups (Supporting Table 2).
Our data showed that the prevalence of lifetime 
tobacco use was higher in era 2 patients compared with 
era 1 patients (62% versus 41%). According to previous 
studies, approximately 60% of LT candidates reported a 
lifetime history of cigarette smoking with the percent-
age as high as 75% among ALD patients.(20,21) Among 
the smokers, one-third to one-half achieved abstinence 
from tobacco while waiting for LT.(20) Among our 
patients with a lifetime smoking history, 23% of patients 
in era 1 and 42% of patients in era 2 stopped smoking for 
more than 12 months before the evaluation. In 1 recent 
study, the reliability of patient self-reported tobacco use 
in LT candidates was high, but a 10% deception rate was 
identified.(22) As a result, many centers perform urinary 
screening for cotinine, a metabolite of nicotine, to moni-
tor for ongoing tobacco use and to increase the reliability 
of detection.(23) In our cohort, the estimated deception 
rate was 6%-7% when using urine cotinine screening. 
Following LT, the reported rate of tobacco relapse was 
40%, and it was highest among ALD patients at 58%.(24) 
However, we did not have these post-LT data available 
for analysis in our cohort.
Recent substance use remains a significant concern 
for LT programs and contributes to the decision to list 
or not to list a patient for transplantation. A survey 
study in 2015 showed that most LT programs have 
a policy on tobacco use (75%), most centers required 
cessation before LT (84%), and all centers encouraged 
attempts at tobacco cessation.(7) However, smoking 
was considered an absolute contraindication to LT in 
only 15% of LT programs, and 62% of the programs 
reported offering LT for current smokers.(6)
In our study, we hypothesized that implementation of 
a prohibitive tobacco use policy in August 2013 would 
lead to fewer smokers being listed for LT and a more pro-
longed time to listing from initial evaluation. Contrary 
to our expectations, there was no significant difference 
in the proportion of smokers listed for LT after the pro-
hibitive policy was implemented compared with the 
prior era (13% versus 17%; P = 0.25) despite an increase 
in the proportion of smoking LT candidates (33% ver-
sus 23%; P < 0.005). As expected, there was an increase 
in the proportion of smokers who were excluded from 
transplant listing due to continued tobacco use after the 
policy implementation (4.4% versus 9.6%; P =  0.001; 
Table 2). Furthermore, the median time-to-listing 
period increased significantly after implementation of 
the policy (Table 2). The time-to-listing period length-
ened modestly (30 days) among patients without a his-
tory of recent tobacco use (within the past 12 months) 
but was more prominent (60 days) in the patients with a 
history of recent tobacco use. We attribute the increase 
in evaluation time to the need to treat comorbid SUD 
and psychiatric illnesses as well as the need to achieve 
complete tobacco cessation. In our multivariate model, 
the prohibitive policy era (era 2), a lower MELD score, 
not having children, and lower levels of education were 
all independently associated with a longer time to wait 
listing (Table 3). However, we note that there was a sig-
nificant increase in the time to listing already ongoing in 
era 1 for both smokers and nonsmokers (Fig. 3), which 
may have been, in part, due to the evolving demograph-
ics of LT candidates at our center. For example, the 
median age of our LT candidates continues to increase, 
and there are a larger proportion of patients with ALD 
and NASH being referred who frequently require more 
extensive pretransplant medical evaluation (Fig. 2). 
In addition, the proportion of patients with Medicaid 
insurance, psychiatric comorbidities, and lower lev-
els of family support and education have significantly 
increased over time, and they frequently require more 
resources and time to be cleared for LT listing.(11)
There are several important limitations of our study. 
First, all of the data were retrospectively abstracted 
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from a single center, and consecutive cohorts of 
patients were compared with each other rather than 
with contemporaneous cohorts. However, we note 
that United Network for Organ Sharing and others 
have also reported a recent increase in the proportion 
of adult LT candidates with ALD and NASH being 
referred and listed for LT, enhancing the face validity 
and generalizability of our findings.(25,26) Assessment 
of tobacco use was also gleaned from retrospective 
review of medical and social work notes and did not 
involve direct patient interviews using a standardized 
instrument. Furthermore, our post-LT outcome data 
must be cautiously interpreted and may reflect lead-
time bias due to the shorter duration of follow-up in 
the era 2 versus era 1 LT recipients. Lastly, the num-
ber of observed deaths both before and after LT was 
small, limiting our power and ability to make defin-
itive conclusions regarding risk factors for mortality. 
However, we anticipate that with more prolonged fol-
low-up of LT recipients in era 2 who improved after 
LT, outcomes will be realized in the prior smokers who 
can sustain tobacco cessation after LT as reported by 
others.(3,4)
In conclusion, cigarette smoking puts LT candi-
dates at an increased, but preventable, risk of graft loss, 
malignancy, and premature deaths. Thus, it is medi-
cally justified to completely prohibit tobacco use in 
all LT candidates, as recommended by the AASLD. 
Our study found that implementation of a prohibitive 
tobacco use policy did not impact the proportion of 
initial smoker candidates who were eventually listed 
for LT compared with our prior restrictive policy. 
However, the time to LT listing significantly increased 
among the initial smoker LT candidates who were 
eventually listed in era 2 compared with era 1. This 
latter observation may have been due to the increasing 
proportion of patients with smoking, SUD, and psy-
chiatric comorbidities being referred for LT evaluation 
in era 2 (Table 1). Going forward, all LT candidates 
should be counseled regarding the need for tobacco 
cessation as soon as possible to improve their likeli-
hood of getting listed for LT and to experience more 
favorable outcomes after LT.
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